Parabilis Medicines, Inc. stock analysis: a $3.56B biotech with about $2M of revenue, heavy losses and no model signal. Risks and fundamentals reviewed.
Health Care
-
-
PharmaceuticalsUS Stocks
AbbVie Hits a Two-Year High, but a 117% Payout Ratio and a 50x P/E Temper the Rally
AbbVie Inc. stock analysis: shares at a two-year high with strong cash flow, a 50.69 P/E and a 117% payout ratio. Model signal: Hold.
-
Eli Lilly and Company stock analysis: 38.6% revenue growth, a two-year high and a 46.15 P/E. See how the scores lead to a Hold signal.
-
Health Care ServicesUS Stocks
UnitedHealth Group: Cheap on Cash Flow, but Revenue Has Stopped Growing
UnitedHealth Group Incorporated stock analysis: a 7.4% free cash flow yield and 22.74 P/E, but revenue is down 0.4%. See the Hold signal explained.
-
BiotechnologyUS Stocks
Relay Therapeutics Hits Its Two-Year High With $10M in Sales and a $117M Cash Burn
Relay Therapeutics, Inc. stock analysis: $117M cash burn, $10M revenue and a two-year high. See what the Quality, Growth and Opportunity scores show.
-
Weekly Wrap
Energy and Technology Drag S&P 500 Down 2.18% as Communication Services Defies the Selloff
S&P 500 dropped 2.18% for the week ending Nov 7, 2026. See top and worst sectors including Communication Services and Technology.
-
Discover the S&P 500 weekly recap for October 31, 2026, with a -1.26% return and top sectors Health Care, Materials, Utilities.